{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T14:58:37Z","timestamp":1740149917587,"version":"3.37.3"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2018,6,1]],"date-time":"2018-06-01T00:00:00Z","timestamp":1527811200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100005788","name":"Medical University of Vienna","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100005788","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["memo"],"published-print":{"date-parts":[[2018,6]]},"DOI":"10.1007\/s12254-018-0409-x","type":"journal-article","created":{"date-parts":[[2018,6,6]],"date-time":"2018-06-06T08:20:20Z","timestamp":1528273220000},"page":"116-121","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Chimeric antigen receptor T\u2011cell therapy\u2014a\u00a0hematological success story"],"prefix":"10.1007","volume":"11","author":[{"given":"Philipp","family":"Wohlfarth","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nina","family":"Worel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Georg","family":"Hopfinger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,6,6]]},"reference":[{"issue":"9","key":"409_CR1","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1038\/nrc.2016.97","volume":"16","author":"AD Fesnak","year":"2016","unstructured":"Fesnak AD, June CH, Levine BL. Engineered T cells: the promise and challenges of cancer immunotherapy. Nat Rev Cancer. 2016;16(9):566\u201381.","journal-title":"Nat Rev Cancer"},{"issue":"9","key":"409_CR2","doi-asserted-by":"publisher","first-page":"1183","DOI":"10.15252\/emmm.201607485","volume":"9","author":"J Hartmann","year":"2017","unstructured":"Hartmann J, Schussler-Lenz M, Bondanza A, Buchholz CJ. Clinical development of CAR T cells-challenges and opportunities in translating innovative treatment concepts. EMBO Mol Med. 2017;9(9):1183\u201397.","journal-title":"EMBO Mol Med"},{"issue":"1","key":"409_CR3","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1038\/nrclinonc.2017.128","volume":"15","author":"JN Brudno","year":"2018","unstructured":"Brudno JN, Kochenderfer JN. Chimeric antigen receptor T\u2011cell therapies for lymphoma. Nat Rev Clin Oncol. 2018;15(1):31\u201346.","journal-title":"Nat Rev Clin Oncol"},{"issue":"7","key":"409_CR4","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1084\/jem.20050732","volume":"202","author":"L Gattinoni","year":"2005","unstructured":"Gattinoni L, Finkelstein SE, Klebanoff CA, Antony PA, Palmer DC, Spiess PJ, Hwang LN, Yu Z, Wrzesinski C, Heimann DM, et al. Removal of homeostatic cytokine sinks by lymphodepletion enhances the efficacy of adoptively transferred tumor-specific CD8+ T cells. J\u00a0Exp Med. 2005;202(7):907\u201312.","journal-title":"J Exp Med"},{"issue":"19","key":"409_CR5","doi-asserted-by":"publisher","first-page":"3875","DOI":"10.1182\/blood-2010-01-265041","volume":"116","author":"JN Kochenderfer","year":"2010","unstructured":"Kochenderfer JN, Yu Z, Frasheri D, Restifo NP, Rosenberg SA. Adoptive transfer of syngeneic T cells transduced with a\u00a0chimeric antigen receptor that recognizes murine CD19 can eradicate lymphoma and normal B cells. Blood. 2010;116(19):3875\u201386.","journal-title":"Blood"},{"issue":"303","key":"409_CR6","doi-asserted-by":"publisher","first-page":"303ra139","DOI":"10.1126\/scitranslmed.aac5415","volume":"7","author":"DL Porter","year":"2015","unstructured":"Porter DL, Hwang WT, Frey NV, Lacey SF, Shaw PA, Loren AW, Bagg A, Marcucci KT, Shen A, Gonzalez V, et\u00a0al. Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia. Sci Transl Med. 2015;7(303):303ra139.","journal-title":"Sci Transl Med"},{"issue":"26","key":"409_CR7","doi-asserted-by":"publisher","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","volume":"377","author":"SS Neelapu","year":"2017","unstructured":"Neelapu SS, Locke FL, Bartlett NL, Lekakis LJ, Miklos DB, Jacobson CA, Braunschweig I, Oluwole OO, Siddiqi T, Lin Y, et al. Axicabtagene ciloleucel CAR T\u2011cell therapy in refractory large B\u2011cell lymphoma. N\u00a0Engl J Med. 2017;377(26):2531\u201344.","journal-title":"N Engl J Med"},{"issue":"12","key":"409_CR8","doi-asserted-by":"publisher","first-page":"2709","DOI":"10.1182\/blood-2011-10-384388","volume":"119","author":"JN Kochenderfer","year":"2012","unstructured":"Kochenderfer JN, Dudley ME, Feldman SA, Wilson WH, Spaner DE, Maric I, Stetler-Stevenson M, Phan GQ, Hughes MS, Sherry RM, et al. B\u2011cell depletion and remissions of malignancy along with cytokine-associated toxicity in a\u00a0clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells. Blood. 2012;119(12):2709\u201320.","journal-title":"Blood"},{"issue":"2","key":"409_CR9","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1182\/blood-2014-05-552729","volume":"124","author":"DW Lee","year":"2014","unstructured":"Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014;124(2):188\u201395.","journal-title":"Blood"},{"key":"409_CR10","doi-asserted-by":"publisher","first-page":"16011","DOI":"10.1038\/mto.2016.11","volume":"3","author":"CL Bonifant","year":"2016","unstructured":"Bonifant CL, Jackson HJ, Brentjens RJ, Curran KJ. Toxicity and management in CAR T\u2011cell therapy. Mol Ther Oncolytics. 2016;3:16011.","journal-title":"Mol Ther Oncolytics"},{"issue":"5","key":"409_CR11","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1056\/NEJMoa1709866","volume":"378","author":"SL Maude","year":"2018","unstructured":"Maude SL, Laetsch TW, Buechner J, Rives S, Boyer M, Bittencourt H, Bader P, Verneris MR, Stefanski HE, Myers GD, et al. Tisagenlecleucel in children and young adults with B\u2011cell lymphoblastic leukemia. N\u00a0Engl J Med. 2018;378(5):439\u201348.","journal-title":"N Engl J Med"},{"issue":"16","key":"409_CR12","doi-asserted-by":"publisher","first-page":"1800","DOI":"10.1182\/blood-2017-03-769620","volume":"130","author":"M Crump","year":"2017","unstructured":"Crump M, Neelapu SS, Farooq U, Van Den Neste E, Kuruvilla J, Westin J, Link BK, Hay A, Cerhan JR, Zhu L, et al. Outcomes in refractory diffuse large B\u2011cell lymphoma: results from the international SCHOLAR-1 study. Blood. 2017;130(16):1800\u20138.","journal-title":"Blood"},{"issue":"26","key":"409_CR13","doi-asserted-by":"publisher","first-page":"2545","DOI":"10.1056\/NEJMoa1708566","volume":"377","author":"SJ Schuster","year":"2017","unstructured":"Schuster SJ, Svoboda J, Chong EA, Nasta SD, Mato AR, Anak O, Brogdon JL, Pruteanu-Malinici I, Bhoj V, Landsburg D, et al. Chimeric antigen receptor T cells in refractory B\u2011cell lymphomas. N\u00a0Engl J Med. 2017;377(26):2545\u201354.","journal-title":"N Engl J Med"},{"issue":"Suppl 1","key":"409_CR14","first-page":"577","volume":"130","author":"SJ Schuster","year":"2017","unstructured":"Schuster SJ, Bishop MR, Tam CS, Waller EK, Borchmann P, McGuirk JP, Jaeger U, Jaglowski S, Andreadis C, Westin JR, et al. Primary analysis of Juliet: a global, pivotal, phase 2 trial of CTL019 in adult patients with relapsed or refractory diffuse large B\u2011cell lymphoma. Blood. 2017;130(Suppl 1):577\u2013577.","journal-title":"Blood"},{"issue":"Suppl 1","key":"409_CR15","first-page":"581","volume":"130","author":"JS Abramson","year":"2017","unstructured":"Abramson JS, Palomba ML, Gordon LI, Lunning MA, Arnason JE, Wang M, Forero A, Maloney DG, Albertson T, Garcia J, et al. High durable CR rates in relapsed\/refractory (R\/R) aggressive B\u2011NHL treated with the CD19-directed CAR T cell product JCAR017 (TRANSCEND NHL 001): defined composition allows for dose-finding and definition of pivotal cohort. Blood. 2017;130(Suppl 1):581\u2013581.","journal-title":"Blood"},{"issue":"1","key":"409_CR16","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13045-016-0379-6","volume":"10","author":"E Zhang","year":"2017","unstructured":"Zhang E, Xu H. A new insight in chimeric antigen receptor-engineered T cells for cancer immunotherapy. J\u00a0Hematol Oncol. 2017;10(1):1.","journal-title":"J Hematol Oncol"},{"issue":"2","key":"409_CR17","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1016\/j.bbmt.2016.09.002","volume":"23","author":"SS Kenderian","year":"2017","unstructured":"Kenderian SS, Porter DL, Gill S. Chimeric antigen receptor T cells and hematopoietic cell transplantation: how not to put the CART before the horse. Biol Blood Marrow Transplant. 2017;23(2):235\u201346.","journal-title":"Biol Blood Marrow Transplant"},{"issue":"8","key":"409_CR18","doi-asserted-by":"publisher","first-page":"3130","DOI":"10.1172\/JCI83092","volume":"126","author":"L Cherkassky","year":"2016","unstructured":"Cherkassky L, Morello A, Villena-Vargas J, Feng Y, Dimitrov DS, Jones DR, Sadelain M, Adusumilli PS. Human CAR T cells with cell-intrinsic PD-1 checkpoint blockade resist tumor-mediated inhibition. J\u00a0Clin Invest. 2016;126(8):3130\u201344.","journal-title":"J Clin Invest"},{"key":"409_CR19","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1186\/s40425-017-0246-1","volume":"5","author":"D Schneider","year":"2017","unstructured":"Schneider D, Xiong Y, Wu D, Nlle V, Schmitz S, Haso W, Kaiser A, Dropulic B, Orentas RJ. A tandem CD19\/CD20 CAR lentiviral vector drives on-target and off-target antigen modulation in leukemia cell lines. J\u00a0Immunother Cancer. 2017;5:42.","journal-title":"J Immunother Cancer"},{"issue":"8","key":"409_CR20","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1182\/blood-2016-09-738245","volume":"129","author":"EA Chong","year":"2017","unstructured":"Chong EA, Melenhorst JJ, Lacey SF, Ambrose DE, Gonzalez V, Levine BL, June CH, Schuster SJ. PD-1 blockade modulates chimeric antigen receptor (CAR)-modified T cells: refueling the CAR. Blood. 2017;129(8):1039\u201341.","journal-title":"Blood"},{"issue":"16","key":"409_CR21","doi-asserted-by":"publisher","first-page":"1803","DOI":"10.1200\/JCO.2016.71.3024","volume":"35","author":"JN Kochenderfer","year":"2017","unstructured":"Kochenderfer JN, Somerville RPT, Lu T, Shi V, Bot A, Rossi J, Xue A, Goff SL, Yang JC, Sherry RM, et al. Lymphoma remissions caused by anti-CD19 chimeric antigen receptor T cells are associated with high serum interleukin-15 levels. J\u00a0Clin Oncol. 2017;35(16):1803\u201313.","journal-title":"J Clin Oncol"},{"issue":"11","key":"409_CR22","doi-asserted-by":"publisher","first-page":"2684","DOI":"10.1158\/1078-0432.CCR-15-1527","volume":"22","author":"M Ruella","year":"2016","unstructured":"Ruella M, Kenderian SS, Shestova O, Fraietta JA, Qayyum S, Zhang Q, Maus MV, Liu X, Nunez-Cruz S, Klichinsky M, et al. The addition of the BTK inhibitor Ibrutinib to anti-CD19 chimeric antigen receptor T cells (CART19) improves responses against mantle cell Lymphoma. Clin Cancer Res. 2016;22(11):2684\u201396.","journal-title":"Clin Cancer Res"},{"issue":"7643","key":"409_CR23","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1038\/nature21405","volume":"543","author":"J Eyquem","year":"2017","unstructured":"Eyquem J, Mansilla-Soto J, Giavridis T, van der Stegen SJ, Hamieh M, Cunanan KM, Odak A, Gonen M, Sadelain M. Targeting a\u00a0CAR to the TRAC locus with CRISPR\/Cas9 enhances tumour rejection. Nature. 2017;543(7643):113\u20137.","journal-title":"Nature"},{"issue":"3","key":"409_CR24","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1038\/mt.2015.197","volume":"24","author":"MJ Osborn","year":"2016","unstructured":"Osborn MJ, Webber BR, Knipping F, Lonetree CL, Tennis N, DeFeo AP, McElroy AN, Starker CG, Lee C, Merkel S, et\u00a0al. Evaluation of TCR gene editing achieved by TALENs, CRISPR\/Cas9, and megaTAL nucleases. Mol Ther. 2016;24(3):570\u201381.","journal-title":"Mol Ther"},{"issue":"5","key":"409_CR25","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1056\/NEJMoa1709919","volume":"378","author":"JH Park","year":"2018","unstructured":"Park JH, Riviere I, Gonen M, Wang X, Senechal B, Curran KJ, Sauter C, Wang Y, Santomasso B, Mead E, et al. Long-term follow-up of CD19 CAR therapy in acute lymphoblastic leukemia. N\u00a0Engl J Med. 2018;378(5):449\u201359.","journal-title":"N Engl J Med"},{"issue":"5","key":"409_CR26","doi-asserted-by":"publisher","first-page":"1156","DOI":"10.1158\/1078-0432.CCR-16-1365","volume":"23","author":"CM Wang","year":"2017","unstructured":"Wang CM, Wu ZQ, Wang Y, Guo YL, Dai HR, Wang XH, Li X, Zhang YJ, Zhang WY, Chen MX, et al. Autologous T cells expressing CD30 chimeric antigen receptors for relapsed or refractory hodgkin lymphoma: an open-label phase I trial. Clin Cancer Res. 2017;23(5):1156\u201366.","journal-title":"Clin Cancer Res"},{"issue":"9","key":"409_CR27","doi-asserted-by":"publisher","first-page":"3462","DOI":"10.1172\/JCI94306","volume":"127","author":"CA Ramos","year":"2017","unstructured":"Ramos CA, Ballard B, Zhang H, Dakhova O, Gee AP, Mei Z, Bilgi M, Wu MF, Liu H, Grilley B, et al. Clinical and immunological responses after CD30-specific chimeric antigen receptor-redirected lymphocytes. J\u00a0Clin Invest. 2017;127(9):3462\u201371.","journal-title":"J Clin Invest"},{"issue":"1","key":"409_CR28","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1038\/nm.4441","volume":"24","author":"TJ Fry","year":"2018","unstructured":"Fry TJ, Shah NN, Orentas RJ, Stetler-Stevenson M, Yuan CM, Ramakrishna S, Wolters P, Martin S, Delbrook C, Yates B, et al. CD22-targeted CAR T cells induce remission in B\u2011ALL that is naive or resistant to CD19-targeted CAR immunotherapy. Nat Med. 2018;24(1):20\u20138.","journal-title":"Nat Med"},{"key":"409_CR29","doi-asserted-by":"publisher","first-page":"16002","DOI":"10.1038\/sigtrans.2016.2","volume":"1","author":"WY Zhang","year":"2016","unstructured":"Zhang WY, Wang Y, Guo YL, Dai HR, Yang QM, Zhang YJ, Zhang Y, Chen MX, Wang CM, Feng KC, et al. Treatment of CD20-directed chimeric antigen receptor-modified T cells in patients with relapsed or refractory B\u2011cell non-hodgkin lymphoma: an early phase IIa trial report. Signal Transduct Target Ther. 2016;1:16002.","journal-title":"Signal Transduct Target Ther"},{"issue":"Suppl 1","key":"409_CR30","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1182\/blood.V130.Suppl_1.740.740","volume":"130","author":"JG Berdeja","year":"2017","unstructured":"Berdeja JG, Lin Y, Raje N, Munshi N, Siegel D, Liedtke M, Jagannath S, Maus MV, Turka A, Lam LP, et al. Durable clinical responses in heavily pretreated patients with relapsed\/refractory multiple myeloma: updated results from a\u00a0multicenter study of bb2121 anti-Bcma CAR T cell therapy. Blood. 2017;130(Suppl 1):740\u2013740.","journal-title":"Blood"}],"container-title":["memo - Magazine of European Medical Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12254-018-0409-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12254-018-0409-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12254-018-0409-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,25]],"date-time":"2022-08-25T02:57:42Z","timestamp":1661396262000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12254-018-0409-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,6]]},"references-count":30,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2018,6]]}},"alternative-id":["409"],"URL":"https:\/\/doi.org\/10.1007\/s12254-018-0409-x","relation":{},"ISSN":["1865-5041","1865-5076"],"issn-type":[{"type":"print","value":"1865-5041"},{"type":"electronic","value":"1865-5076"}],"subject":[],"published":{"date-parts":[[2018,6]]},"assertion":[{"value":"4 February 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 May 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 June 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"P.\u00a0Wohlfarth, N.\u00a0Worel, and G.\u00a0Hopfinger declare that they have no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}